Evidence map›Paper›PMID 37774700›Full record

ArticleCancer cell2023

Beyond bacteria: How the intratumor mycobiome modulates lung adenocarcinoma progression.

Zahraa Rahal, Humam Kadara

Open access · greenAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Mycobiome: an underexplored kingdom in cancer.Microbiology and molecular biology reviews : MMBR · 2025
    Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Zahraa RahalDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Humam KadaraDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; UTHealth Houston Graduate School of Biomedical Sciences (GSBS), The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: hkadara@mdanderson.org.
The University of Texas Health Science Center at Houston · USThe University of Texas MD Anderson Cancer Center · US

Funding

Interplay between host microbiome and immunomodulatory responses in the pathogenesis of Kras mutant lung cancerR01CA248731 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KADARA, HUMAM, MOGHADDAM, SEYED JAVAD MIRHASSANI · 2021 to 2025
$2.5M
NCI NIH HHS R01 CA248731
6 · The paper itself

Abstract

Increasing evidence suggests that tumors harbor diverse microbiomes, adding complexity to the tumor microenvironment. In this issue of Cancer Cell, Liu et al. highlight the role of the intratumor mycobiome, specifically Aspergillus sydowii, in promoting lung adenocarcinoma progression. A. sydowii enhances the recruitment and activation of myeloid-derived suppressor cells via IL-1β signaling driven by the β-glucan-mediated Dectin-1/CARD9 pathway.

Indexed as

Adenocarcinoma of Lungbeta-GlucansMycobiomeBacteriaHumansSignal TransductionTumor Microenvironmentbeta-Glucans

Identifiers

PMID37774700
PMCPMC10901296
OpenAlexW4387131817

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.